Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13236223 | 0.90 | LMNA (0.46) | PTGDR2TBXA2RPTGDRHIF1AEPAS1 | |
| SCHEMBL2939746 | 0.84 | KDM4E (0.56) | PTGDR2 | |
| SCHEMBL2941686 | 0.83 | PTGDR2 (0.56) | PTGDR2TBXA2RPTGDRHIF1AEPAS1 | |
| SCHEMBL12415759 | 0.81 | PTGDR2 (0.69) | PTGDR2TBXA2RPTGDRHIF1AEPAS1 | |
| SCHEMBL12415748 | 0.81 | PTGDR2 (0.69) | PTGDR2TBXA2RPTGDRHIF1AEPAS1 | |
| SCHEMBL2945205 | 0.77 | GABRP (0.38) | — | |
| SCHEMBL13236209 | 0.76 | PTGDR2 (0.47) | PTGDR2TBXA2RPTGDRHIF1AEPAS1 | |
| SCHEMBL13236240 | 0.75 | PTGDR2 (0.47) | PTGDR2 | |
| SCHEMBL5959159 | 0.74 | HIF1A (0.45) | PTGDR2TBXA2RPTGDRHIF1AEPAS1 | |
| SCHEMBL15749941 | 0.74 | PTGDR2 (0.61) | PTGDR2TBXA2RPTGDRHIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | claimed |
| EP-1718649-B1 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | claimed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | claimed |
| EP-1718649-A2 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | Actimis Pharmaceuticals, Inc., (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005073234-A2 | IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | WO | claimed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1718649-B1 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1718649-A2 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | Actimis Pharmaceuticals, Inc., (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005073234-A2 | IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | HRH2, CCR2, HRH1 | PTGDR2 56/4885TBXA2R 88/4885PTGDR 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.